HWAM
NGM

Hennion & Walsh Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Hennion & Walsh Asset Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-70,636
Closed -$112K – 909
2024
Q1 		$112K Buy
70,636
+4,700
+7% +$6.97K 0.01% 828
2023
Q4 		$56.6K Buy
65,936
+8,069
+14% +$7.08K ﹤0.01% 816
2023
Q3 		$61.9K Buy
57,867
+2,298
+4% +$4.75K ﹤0.01% 794
2023
Q2 		$144K Sell
55,569
-1,497
-3% -$5.34K 0.01% 771
2023
Q1 		$233K Sell
57,066
-1,803
-3% -$8.33K 0.01% 706
2022
Q4 		$296K Sell
58,869
-116,314
-66% -$729K 0.02% 633
2022
Q3 		$2.29M Buy
175,183
+5,846
+3% +$88.5K 0.15% 175
2022
Q2 		$2.17M Sell
169,337
-76,985
-31% -$1.07M 0.13% 190
2022
Q1 		$3.76M Sell
246,322
-10,436
-4% -$163K 0.2% 140
2021
Q4 		$4.55M Sell
256,758
-20,232
-7% -$388K 0.22% 121
2021
Q3 		$5.82M Sell
276,990
-9,468
-3% -$208K 0.31% 80
2021
Q2 		$5.65M Buy
286,458
+26,617
+10% +$623K 0.3% 78
2021
Q1 		$7.55M Buy
+259,841
New +$7.27M 0.45% 40

Hennion & Walsh Asset Management's NGM Position: Q2 2024 in Review

Hennion & Walsh Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 70,636 shares — an estimated $112K sold.

Hennion & Walsh Asset Management first reported a position in NGM in Q1 2021 and held it in 13 quarters. The position peaked at $7.55M in Q1 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Hennion & Walsh Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 70,636 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $112K.
  • Hennion & Walsh Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
  • Hennion & Walsh Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $7.55M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2024, filed 19 Jul 2024.